Agilent Technologies, Inc.

New York Stock Exchange
Back to all articles
Bullish +72

Agilent Technologies “in country, for country” strategy helps mitigate supply disruptions

📈 Agilent Technologies' "in-country, for country" strategy has successfully mitigated supply disruptions despite global challenges like the war in West Asia.

🏭 The company launched a new Customer Experience Center in Mumbai featuring technology demonstrations within an integrated facility.

🌍 Jonah Kirkwood, SVP & CCO, stated that supply chain resilience was a critical focus over the past two years through parallel manufacturing and diversification.

✅ Agilent confirmed it has not seen any material impact on its supply chain, prioritizing employee and distributor safety during humanitarian crises.

💰 In December, Agilent opened a refurbishment center in Manesar, Haryana, offering certified pre-owned instruments restored to factory-grade standards.

🤝 These refurbished products come with the same one-year warranty as new instruments to provide sustainability and affordability benefits.

🔄 Sourcing for these refurbished units is done entirely within India, aligning with the "within-India-for-India" focus.

💼 VP Bharat Bhardwaj highlighted the service's value for startups and small labs that may lack capital for new high-end instruments.

📊 Customers can access advanced technologies through flexible financial solutions including subscriptions, rentals, or pay-for-project models.

📈 The company is capitalizing on Indian firms expanding in the CDMO segment and the production of GLP-1 drugs like semaglutide.

💵 Agilent's total revenue stands at $6.95 billion for 2025, with the Asia-Pacific region contributing 15% to 18% as the fastest-growing area.

🇮🇳 India represents a crown jewel in Agilent's growth story across pharma, chemical, and environmental testing segments.

Bullish Signals
  • Agilent Technologies' "in country, for country" strategy has successfully mitigated supply disruptions, with the company reporting no material impact to its supply chain despite global challenges like the war in West Asia.
  • Sustained growth is being driven by the Asia-Pacific region, which contributes 15 to 18% of total revenue and represents one of Agilent's fastest growing regions for the year 2025.
  • India is described as an "absolute crown jewel" in Agilent's growth story, demonstrating consistent and sustained growth across key segments including pharma, biopharma, chemical materials, and environmental tools.
  • The Customer Experience Center in Mumbai showcases technology demonstrations in an integrated facility to meet customer needs in critical areas like pharmaceuticals, diagnostics, and environmental testing.
  • Agilent recently opened a refurbishment center in Manesar to deliver certified pre-owned instruments at very affordable costs, with offerings supported by flexible financing solutions such as subscriptions and rental models.
  • Customers receive a one-year warranty on refurbished products, the same as new instrument purchases, while sourcing components directly from within India to enhance affordability and sustainability.
Risk Factors
  • Agilent relies on a complex global supply chain that remains vulnerable to disruptions caused by geopolitical tensions, including the war in West Asia which recently impacted silver futures and market sentiment.
  • While management claims no material impact, the company's 15-18% revenue from Asia-Pacific makes it highly dependent on this fastest-growing region, creating concentration risk if regional growth slows due to macroeconomic instability or ongoing conflicts.
  • The company spun out from Hewlett Packard in 1999 and marked its 25th anniversary as an independent entity, indicating a mature but potentially stagnant phase of growth that requires sustained innovation to maintain competitiveness against emerging players in scientific tools.
Full Analysis
Agilent Technologies has successfully mitigated supply disruptions through its "in country, for country" strategy despite global challenges arising from geopolitical instability in West Asia. According to Jonah Kirkwood, Senior Vice President and Chief Commercial Officer at the US-based company, Agilent focused on activating an area dedicated to supply chain resilience over the past 18 months by parallelly starting in-country manufacturing and diversifying supply chains. The company also analyzed shipping routes extensively to ensure robustness. Despite these ongoing global tensions, which led to a recent decline in silver futures due to Iran-related concerns, Agilent reported no material impact on its operations, with management prioritizing the safety of employees and distributors above all else during any humanitarian situations. To further strengthen its local presence, Agilent launched its Customer Experience Center in Mumbai, an integrated facility designed for technology demonstrations catering to key sectors such as pharmaceuticals, biopharma, diagnostics, chemicals, food safety, and environmental testing. Complementing this launch is a refurbishment center opened in Manesar (Haryana) last December, which restores instruments to factory-grade standards and offers certified pre-owned products supported by flexible financing solutions like subscriptions or rental models. Bharat Bhardwaj, Agilent's Vice President for Asia Pacific, noted that these initiatives are particularly significant for startups and small laboratories that may lack sufficient capital for new instruments but require access to the latest technology at affordable costs. Financially, Agilent is valued at $6.95 billion, with approximately 15% to 18% of its total revenue coming from the Asia-Pacific region, which is currently identified as the company's fastest-growing market. India represents a key segment within this growth story, contributing substantially across focus areas including pharma and biopharma, chemical and advanced materials, and environmental and clinical tools. As patents for innovative products like semaglutide expire, Agilent has increased its activity to support Indian companies expanding in the contract development and manufacturing organization (CDMO) space, ensuring they have the necessary instruments to continue producing GLP-1 drugs and other advanced therapies while maintaining sustainability and affordability benefits.